GLIS2

Across TCGA pan-cancer cohorts, GLIS2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of GLIS2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where GLIS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GLIS2 is over-expressed in tumor, although a few such as KICH and UCEC show the opposite, repressed pattern.

KIRP, HNSC, and KICH are the cancer types where GLIS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GLIS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	II,III,IV	+1.058	<.001	11	view →
HNSC	All	All	+1.355	<.001	10	view →
KICH	Male	All	−1.091	<.001	10	view →
LIHC	Female	III,IV	+2.995	<.001	7	view →
UCEC	All	All	−1.276	<.001	6	view →
LUSC	All	II,III,IV	−0.906	<.001	6	view →
BRCA	All	III,IV	+0.884	<.001	6	view →
CHOL	Female	All	+3.559	<.001	5	view →
STAD	Male	II,III,IV	+1.304	.005	4	view →
LUAD	All	All	−0.581	<.001	3	view →
COAD	Female	All	+0.429	.029	3	view →
PRAD	All	All	−0.800	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

GLIS2–KIRP

Open the KIRP breakdown →